智飞生物前三季度净利亏损12.06亿元

Core Insights - The company reported a significant decline in revenue and a net loss for the first three quarters of 2025, indicating a challenging market environment [1] Financial Performance - The company achieved an operating revenue of 7.627 billion yuan, representing a year-on-year decrease of 66.53% [1] - The net profit attributable to shareholders was -1.206 billion yuan, marking a shift from profit to loss compared to the previous year [1] Reasons for Revenue Decline - The company attributed the decrease in revenue to underperformance in market sales, which did not meet expectations [1]